WO2023235982A1

WO2023235982A1 - Antibodies targeting integrin beta-2

Info

Publication number: WO2023235982A1
Application number: PCT/CA2023/050791
Authority: WO
Inventors: Sachdev SINGH SIDHU
Original assignee: Individual
Current assignee: Individual
Priority date: 2022-06-08
Filing date: 2023-06-08
Publication date: 2023-12-14
Anticipated expiration: 2024-12-08
Also published as: US12606628B2; AU2023283275A1; EP4536705A1; EP4536706A1; EP4536705A4; JP2025521246A; CA3258316A1; WO2023235971A1; CN119654348A; IL317533A; ZA202500100B; US20240101680A1; EP4536706A4; KR20250021381A; CA3258440A1

Abstract

Provided herein are antibodies that specifically target integrin beta-2 and compositions comprising such antibodies for therapeutic and diagnostic applications. The antibodies comprise an integrin beta-2 binding domain comprising a heavy chain variable region comprising an HCDR1 sequence comprising ISYYYM, an HCDR2 sequence comprising SISSSSGYTY; and an HCDR3 sequence comprising GAM; and a light chain variable region comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising FSSGSWAPI.

Description

Antibodies Targeting Integrin Beta-2

Technical Field

[0001] The embodiments disclosed herein relate to antibody therapeutics, and, in particular to antibodies that specifically target integrin beta-2.

Introduction

[0002] Development of safe and effective immunotherapies has proven difficult given the lack of characterized cancer-specific surface markers. It has been hypothesized that given aberrancies in tumor signaling, metabolism, or cellmicroenvironment communication - all of which heavily involve membrane proteins - cancer-specific surface protein conformations may in fact be widespread. In particular, integrin beta-2, may be a promising immunotherapeutic target, expressed widely across cell lines and patient tumors.

[0003] Accordingly, there is a need for novel antibodies that specifically target integrin beta-2 for further development of targeted cancer immunotherapies and diagnostics.

Summary

[0004] Phage display selection was used to identify anti-integrin beta-2 antibodies that can be used for diagnostic and therapeutic purposes.

[0005] In some embodiments, provided is an anti-integrin beta-2 antibody having a KD less than about 10 nM.

[0006] In some embodiments, the antibody includes an anti-integrin beta-2 binding domain having at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, the anti-integrin beta-2 binding domain comprises an HCDR3 of SEQ ID NO:2 and an LCDR3 of SEQ ID NO:3. In some embodiments, the anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3.

[0007] In some embodiments, the anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:2. In some embodiments, the anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:2. In some embodiments, the anti- integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:2.

[0008] In some embodiments, the anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:3. In some embodiments, the anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 3 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:3. In some embodiments, the anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:3.

[0009] In some embodiments, the anti-integrin beta-2 binding domain comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, the anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO:2 and having at least 95% identity to SEQ ID NO:2; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:3 and having at least 95% identity to SEQ ID NO:3..

[0010] Other aspects and features will become apparent, to those ordinarily skilled in the art, upon review of the following description of some exemplary embodiments. Brief Description of the Drawings

[0011] The drawings included herewith are for illustrating various examples of articles, methods, and apparatuses of the present specification. In the drawings:

[0012] FIG. 1 is a diagram of phage-fab display selection strategy for developing anti-integrin beta-2 antibodies;

[0013] FIGS. 2A-2D are representative ELISA plots for phage selected anti-integrin beta-2 antibody candidates;

[0014] FIG. 3 is a table showing the complementarity-determining regions (CDRs) of the anti-integrin beta-2 antibody candidates shown in FIGS. 2A-2D.

[0015] FIGS. 4A-4H are ELISA plots showing integrin beta-2 binding specificity of the antibodies obtained from phage display selection;

[0016] FIG. 5A-5R are representative biolayer interferometry plots showing binding kinetics of antibodies against integrin-2 heterodimers; and

[0017] FIG. 6 is a table showing binding affinities of antibodies against integrin-2 heterodimers from the biolayer interferometry plots shown in FIGS. 5A-5R.

Detailed Description

[0018] Various compositions of matter will be described below to provide an example of each claimed embodiment. No embodiment described below limits any claimed embodiment and any claimed embodiment may cover compositions that differ from those described below. The claimed embodiments are not limited to compositions having all of the features of any one composition described below or to features common to multiple or all of the compositions described below.

[0019] The term "about" as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. For example, for KD and IC50 values ± 20%, ± 10%, or ± 5%, are within the intended meaning of the recited value.

[0020] The term integrin beta-2 or Integrin beta-2, also known as CD18, LAD, LCAMB, LFA-1 , MAC-1 , MF17, MFI7, or integrin subunit beta 2, as used herein, refers to a polypeptide that is encoded by a ITGB2 gene (chr21 :44, 885, 949-44, 931 ,989 (GRCH38/hg38), cytogenetically localized to human chromosome 21 q22.3 by HGNC, Entrez Gene, and Ensembl (genomic coordinates (GRCh38/hg38 assembly December 2013:) and plays a role in cell adhesion, cell-surface-mediated sequencing, and immune responses. An illustrative human integrin beta-2 protein sequence encoded by a human ITGB2 gene, P05107-1 , is available under Uniprot number P05107 and is provided as SEQ ID NO: I. integrin beta-2 can bind to a number of alpha chains and thus can from multiple heterodimers, but also exists in soluble, ligand binding forms. Deficiencies in Itgb2 expression can lead to adhesion defects in circulating white blood cells in humans, reducing the immune system's ability to fight off foreign invaders. Illustrative Integrin beta- 2 heterodimers include, e.g., integrin ITGAL/ITGB2, which is a receptor for ICAM1 , ICAM2, ICAM3 and ICAM4, and is also a receptor for the secreted form of ubiquitin-like protein ISG15; integrins ITGAM/ITGB2 and ITGAX/ITGB2, which are receptors for the iC3b fragment of the third complement component and for fibrinogen; integrin ITGAX/ITGB2, which recognizes the sequence G-P-R in fibrinogen alpha-chain, Integrin ITGAM/ITGB2, which recognizes P1 and P2 peptides of fibrinogen gamma chain and is also a receptor for factor X; and integrin ITGAD/ITGB2, which is a receptor for ICAM3 and VCAM1.

[0021] The terms "anti-integrin beta-2 antibody," "integrin beta-2 specific antibody," "integrin beta-2 antibody," and "anti-integrin beta-2" are used synonymously herein to refer to an antibody that specifically binds to integrin beta-2. An illustrative human integrin beta-2 sequence is provided in SEQ ID NO:1.

[0022] An "anti-integrin beta-2 binding domain" as used herein refers to an antigen binding domain comprising a VH and a VL region of an anti-integrin beta-2 antibody as described herein, which antigen binding domain binds to integrin beta-2.

[0023] An anti-integrin beta-2 antibody of the present disclosure binds to integrin beta-2. An active state of integrin beta-2 is an extended-open conformation (see, e.g., Nishida et al, Immunity 25:583-94, 2006; Li et al, EMBO J. 36:629-45, 2017). The active conformation (extended-open) has a 4,000-fold increase in ligand affinity compared to the other two states (bent-closed, inactive; and extended-closed (intermediate) (Li et al, 2017, supra). Integrin activation takes place upon cell stimulation through various cell surface receptors. Cell stimulation triggers an inside-out signaling pathway that ultimately recruits cytoplasmic factors such as talin and kindlin to the NPxY motifs of the cytoplasmic tail of the integrin's beta-chain, which causes the cytoplasmic tails of the integrin subunits to separate and switches the integrin to the active (extended-open) conformation.

[0024] As used herein, the term "antibody" refers to a polypeptide comprising a framework region encoded by an immunoglobulin gene, or fragments thereof, that specifically binds and recognizes an antigen, e.g., integrin beta-2. Typically, the "variable region" contains the antigen-binding region of the antibody (or its functional equivalent) and is important in specificity and affinity of binding. The term "antibody" as used herein thus encompasses antigen binding fragments, e.g., an antigen binding domain, or other antigen binding fragment. Antigen binding fragments may be produced by modification of whole antibodies, or produced using recombinant DNA methodologies (e.g., single chain Fv formats).

[0025] An illustrative immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N- terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

[0026] As used herein, "V-region" refers to an antibody, e.g., antibody, variable region domain comprising the segments of Framework 1 , CDR1 , Framework 2, CDR2, and Framework 3, including CDR3 and Framework 4, which segments are added to the V-segment as a consequence of rearrangement of V-region genes during B-cell differentiation.

[0027] As used herein, "complementarity-determining region (CDR)" refers to the three hypervariable regions that interrupt the four "framework" regions of a variable domain. The CDRs are the primary contributors to binding to an epitope of an antigen. The CDRs are referred to as CDR1 , CDR2, and CDR3, numbered sequentially starting from the N-terminus. [0028] The amino acid sequences of the CDRs and framework regions can be determined using various well-known definitions in the art, e.g., Kabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Johnson et al., supra; Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901 -917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)). Definitions of antigen combining sites are also described in the following: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc,M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan 1 ;29(1 ):207-9 (2001 ); MacCallum et al, Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262 (5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin, et al, Methods Enzymol., 203, 121 -153, (1991 ); Pedersen et al, Immunomethods, 1 , 126, (1992); and Rees et al, In Sternberg M.J.E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141 -172 1996). Reference to CDRs as determined by Kabat numbering are based, for example, on Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, MD (1991 )). Chothia CDRs are determined as defined by Chothia (see, e.g., Chothia and Lesk J. Mol. Biol. 196:901 -917 (1987)).

[0029] An "isotype,” as used herein, is a class of antibodies defined by the heavy chain constant region. Antibodies described herein can be of any isotype of isotype class. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the isotype classes, IgG, IgM, IgA, IgD and IgE, respectively. In some embodiments, the IgG is an IgGI, lgG2, lgG3 or lgG4.

[0030] Antibodies can exist as intact immunoglobulins or as any of a number of well-characterized fragments that include specific antigen-binding activity. Such fragments can be produced by digestion with various peptidases. Pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology.

[0031] Antibodies or antigen-binding molecules of the present invention further includes one or more immunoglobulin chains that are chemically conjugated to, or expressed as, fusion proteins with other proteins. It also includes bispecific antibody. A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Other antigen-binding fragments or antibody portions of the invention include single chain variable fragments (scFv) bivalent scFv (diabody), bispecific scFv antibodies where the antibody molecule recognizes two different epitopes, single binding domains (dAbs), and minibodies. The term "antibody" additionally encompasses bispecific and multispecific antibodies as well as any other monovalent, bivalent, or multivalent antibody format.

[0032] The various antibodies or antigen-binding fragments described herein can be produced by enzymatic or chemical modification of the intact antibodies, or synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv), or identified using yeast or phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554, 1990; Boder, et al (2000) Proc. Natl. Acad. Sci. U S. A. 97:10701 ). For example, minibodies can be generated using methods described in the art, e.g., Vaughan and Sollazzo, Comb Chem High Throughput Screen. 4:417-302001 . Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992). Single chain antibodies can be identified using phage display libraries, yeast display, or ribosome display libraries, gene shuffled libraries. Such libraries can be constructed from synthetic, semi-synthetic or native and immunocompetent sources. [0033] A "monoclonal antibody" refers to a clonal preparation of antibodies with a single binding specificity and affinity for a given epitope on an antigen.

[0034] A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region, CDR, or portion thereof) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody (e.g., an enzyme, toxin, hormone, growth factor, drug, etc.); or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity (e.g., CDR and framework regions from different species).

[0035] A "humanized" antibody is an antibody that retains the reactivity of a nonhuman antibody while being less immunogenic in humans. This can be achieved, for instance, by retaining the non-human CDR regions and replacing the remaining parts of the antibody with their human counterparts. In one embodiment, some, most or all of the amino acids outside the CDR domains are replaced with amino acids corresponding to the human immunoglobulin germline, while amino acids within one or more CDR regions are unchanged. In some embodiments, one or more CDR residues may be altered, e.g., to provide a sequence closer to germline or to replace a residue that may impede production.

[0036] The term "specifically bind(s)" or “specially target(s)” refers to a molecule (e.g., antibody or antibody fragment) that binds to a target with at least 2-fold greater affinity than non-target compounds, e.g., at least 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9- fold, 10-fold, 20-fold, 25-fold, 50-fold, or 100-fold greater affinity. For example, an antibody that specifically binds integrin beta-2, typically bind to integrin beta-2, with at least a 2-fold greater affinity than a non-integrin beta-2 target, or in the case of an antibody that specifically binds active Integrin beta-2, an inactive form of integrin beta-2. In some embodiments, an antibody binds to active Integrin beta-2 with a KD that is at least 100- fold greater than its affinity inactive integrin beta-2.

[0037] "Epitope" or "antigenic determinant" refers to a site on an antigen to which an antibody binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996).

[0038] The term "valency" as used herein refers to the number of different binding sites of an antibody for an antigen. A monovalent antibody comprises one binding site for an antigen. A multivalent antibody comprises multiple binding sites.

[0039] The words "protein", "peptide", and "polypeptide" are used interchangeably to denote an amino acid polymer or a set of two or more interacting or bound amino acid polymers. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

[0040] A "flexible linker" as used herein refers to an amino acid sequence that joins domains to provide a certain degree of movement or interaction. Such linkers are generally composed of small, non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids, but may also comprise polar amino acids such as Lys and Glu, e.g., to improve solubility. The small size of these amino acids provides flexibility, and allows for mobility of the connecting functional domains. The incorporation of Ser or Thr can maintain the stability of the linker in aqueous solutions by forming hydrogen bonds with the water molecules, and therefore reduces the unfavorable interaction between the linker and the protein moieties. In some embodiments, flexible linkers are primarily composed of stretches of Gly and Ser residues ("GS" linker). An example of the most widely used flexible linker has the sequence of (Gly-Gly-Gly-Gly-Ser)n. By adjusting the copy number "n", the length of this GS linker can be adjusted to achieve appropriate separation of the functional domains and/or to maintain necessary inter-domain interactions. Besides the GS linkers, many other flexible linkers have been designed for recombinant protein expression.

[0041] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

[0042] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0043] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

[0044] A “substitution” as used herein refers to a substitution of an amino acid such that charge, hydrophobicity, and/or size of the side group chain is maintained. Illustrative sets of amino acids that may be substituted for one another include (i) positively-charged amino acids Lys, Arg and His; (ii) negatively charged amino acids Glu and Asp; (iii) aromatic amino acids Phe, Tyr and Trp; (iv) nitrogen ring amino acids His and Trp; (v) large aliphatic nonpolar amino acids Vai, Leu and lie; (vi) slightly polar amino acids Met and Cys; (vii) small-side chain amino acids Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gin and Pro; (viii) aliphatic amino acids Vai, Leu, lie, Met and Cys; and (ix) small hydroxyl amino acids Ser and Thr. Reference to the charge of an amino acid in this paragraph refers to the charge at physiological pH.

[0045] The terms "nucleic acid" and "polynucleotide" are used interchangeably and as used herein refer to both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. In particular embodiments, a nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide, and combinations thereof. The terms also include, but is not limited to, single- and double-stranded forms of DNA. In addition, a polynucleotide, e.g., a cDNA or mRNA, may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. Nucleic acid molecules, e.g. oligonucleotide probes or primers, may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analogue, nucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.). The above term is also intended to include any topological conformation, including single-stranded, doublestranded, partially duplexed, triplex, hairpinned, circular and padlocked conformations. A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The term also includes codon-optimized nucleic acids that encode the same polypeptide sequence.

[0046] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. A "vector" as used here refers to a recombinant construct in which a nucleic acid sequence of interest is inserted into the vector. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors".

[0047] The terms "identical" or "percent identity," in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (i.e. , about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters, or by manual alignment and visual inspection. See e.g., the NCBI web site at ncbi.nlm.nih.gov/BLAST. Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a nucleotide test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the algorithms can account for gaps and the like. Typically, identity exists over a region comprising an antibody epitope, or a sequence that is at least about 25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length, or over the entire length of the reference sequence.

[0048] The terms "corresponding to," "determined with reference to," or "numbered with reference to" when used in the context of the identification of a given amino acid residue in a polypeptide sequence, refers to the position of the residue of a specified reference sequence when the given amino acid sequence is maximally aligned and compared to the reference sequence. Thus, for example, an amino acid residue in a variable domain polypeptide "corresponds to" an amino acid in the variable domain polypeptide of SEQ ID NO:1 when the residue aligns with the amino acid in SEQ ID NO:1 when optimally aligned to SEQ ID NO:1 . The polypeptide that is aligned to the reference sequence need not be the same length as the reference sequence.

[0049] The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (nonrecombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

[0050] The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

[0051] The term "isolated," when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state. It can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. In particular, an isolated gene is separated from open reading frames that flank the gene and encode a protein other than the gene of interest. The term "purified" denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

[0052] "Subject," "patient," "individual" and like terms are used interchangeably and refer to, except where indicated, mammals such as humans and non-human primates, as well as rabbits, rats, mice, goats, pigs, and other mammalian species. The term does not necessarily indicate that the subject has been diagnosed with a particular disease, but typically refers to an individual under medical supervision. A patient can be an individual that is seeking treatment, monitoring, adjustment or modification of an existing therapeutic regimen, etc.

[0053] "Cancer", "tumor," "transformed" and like terms include precancerous, neoplastic, transformed, and cancerous cells, and can refer to a solid tumor, or a nonsolid cancer. Cancer includes both benign and malignant neoplasms (abnormal growth). The term "cancer" can thus refer to carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, solid and lymphoid cancers, etc. Examples of different types of cancer include, but are not limited to, lung cancer (e.g., non-small cell lung cancer or NSCLC), ovarian cancer, prostate cancer, colorectal cancer, liver cancer (i.e., hepatocarcinoma), renal cancer (i.e., renal cell carcinoma), bladder cancer, breast cancer, thyroid cancer, pleural cancer, pancreatic cancer, uterine cancer, cervical cancer, testicular cancer, anal cancer, pancreatic cancer, bile duct cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, cancer of the central nervous system, skin cancer, choriocarcinoma; head and neck cancer, blood cancer, osteogenic sarcoma, fibrosarcoma, neuroblastoma, glioma, melanoma, B-cell lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, Small Cell lymphoma, Large Cell lymphoma, monocytic leukemia, myelogenous leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (AML), chronic myeloid leukemia (CML), and multiple myeloma. In some embodiments, the antibody compositions and methods described herein can be used for treating cancer.

[0054] The terms "chimeric antigen receptor" and "CAR", used interchangeably herein, refer to artificial multi-module molecules capable of triggering or inhibiting the activation of an immune cell which generally but not exclusively comprise an extracellular domain (e.g., a ligand/antigen binding domain), a transmembrane domain and one or more intracellular signaling domains. The term CAR is not limited specifically to CAR molecules but also includes CAR variants. CAR variants include split CARs wherein the extracellular portion (e.g., the ligand binding portion) and the intracellular portion (e.g., the intracellular signaling portion) of a CAR are present on two separate molecules. CAR variants also include ON-switch CARs which are conditionally activatable CARs, e.g., comprising a split CAR wherein conditional hetero-dimerization of the two portions of the split CAR is pharmacologically controlled. CAR variants also include bispecific CARs, which include a secondary CAR binding domain that can either amplify or inhibit the activity of a primary CAR. CAR variants also include inhibitory chimeric antigen receptors (iCARs) which may, e.g., be used as a component of a bispecific CAR system, where binding of a secondary CAR binding domain results in inhibition of primary CAR activation. CAR molecules and derivatives thereof (i.e. , CAR variants) are described, e.g., in PCT Application No. US2014/016527; Fedorov et al. Sci Transl Med (2013); 5(215):215ra172; Glienke et al. Front Pharmacol (2015) 6:21 ; Kakarla & Gottschalk 52 Cancer J (2014) 20(2): 151 -5; Riddell et al.Cancer J (2014) 20(2): 141 -4; Pegram et al. Cancer J (2014) 20(2): 127-33; Cheadle et al. Immunol Rev (2014) 257(1 ):91 -106; Barrett et al. Annu Rev Med (2014) 65:333-47; Sadelain et al. Cancer Discov (2013) 3(4):388- 98; Cartellieri et al., J Biomed Biotechnol (2010) 956304; the disclosures of which are incorporated herein by reference in their entirety.

[0055] As used herein, the term "immune cells" generally includes white blood cells (leukocytes) which are derived from hematopoietic stem cells (HSC) produced in the bone marrow "Immune cells" includes, e.g., lymphocytes (T cells, B cells, natural killer (NK) cells) and myeloid-derived cells (neutrophil, eosinophil, basophil, monocyte, macrophage, dendritic cells). [0056] "T cell" includes all types of immune cells expressing CD3 including T- helper cells (CD4+ cells), cytotoxic T-cells (CD8+ cells), T-regulatory cells (Treg) and gamma-delta T cells.

[0057] A "cytotoxic cell" includes CD8+ T cells, natural-killer (NK) cells, and neutrophils, which cells are capable of mediating cytotoxicity responses.

Phage display selections of anti-integrin beta-2 antibodies

[0058] Referring to FIG. 1 , illustrated therein is a diagram of a phage display selection strategy used for developing anti-integrin beta-2 antibodies. A previously- described Fab-phage display platform (Persson, et al., J. Mol. Biol. 425: 803-811 , 2013), based on a fully human framework sequence, was used to perform selections versus recombinant integrin beta-2, including Integrin beta-2/lntegrin alpha-M (R and D 4047- AM, Antibody #7061 , #7062, #7063, #7064 #7065), lntegrin-[32/lntegrin alpha-L (R and D 3868-AV, Antibody #7060, #7341 ) and lntegrin-|32/lntegrin alpha-X (R and D 5755-AX, Antibody #7055, #7056, #7057) recombinant heterodimer protein complexes.

[0059] Briefly, integrin beta-2 recombinant protein complexes were immobilized on Maxisorp Immuno plates (ThermoFisher, 12-565-135) and used for positive binding selections with library phage pools that were first exposed to neutravidin coated wells to deplete nonspecific binders. After four rounds of binding selections, clonal phage was prepared and evaluated by phage ELISA and sequencing as previously described (Persson, et al., supra) and summarized below.

[0060] From the initial library diversity of ~10¹⁰ binders, ten initial Fab hits shown in FIGS. 2A-2D and FIG. 3 were identified versus integrin-02 recombinant heterodimer protein complexes. Seven of the Fab hits (#7055, #7056, #7057, #7060, #7061 , #7062, #7063, #7064, #7065, #7341 ) were further validated using bio-layer interferometry (BLI) (see FIGS. 5A-5R and FIG. 6) and non-specific ELISA (see FIGS. 4A-4H) to have binding affinities to integrin beta-2 in the low-nM range and lack of binding to irrelevant proteins, respectively. These Fabs were cloned into a human lgG1 backbone and were purified following recombinant expression in mammalian cells, e.g., Expi93 human embryonic kidney cells or Chinese hamster ovary cells. Antibody production

[0061] Anti-integrin beta-2 antibodies were produced using the human Expi293 expression system (Thermofisher). Expi293 cells at 2 ml volume were transiently transfected with construct DNA using FectoPro transfection reagent (Polyplus Transfection, 101000014). Following a 5-day expression period, the antibodies were purified using rProteinA Sepharasoe (GE Healthcare) and stored in phosphate buffer (50 mM NaH2PO4, 75 mM Na2HPO4, 100 mM H3PO4, 154 mM NaCI).

Bio-Layer Interferometry (BLI) binding assays

[0062] The binding of human integrin beta-2 antibodies was tested against three different Integrin beta-2 complexes including integrin beta-2/integrin alpha-M (R and D 4047-AM), integrin beta-2/integrin alpha-X (R and D 5755-AX), and integrin beta- 2/integrin alpha-L (R and D 3868-AV). To determine the binding kinetic parameters of the antibodies, BLI experiments were performed on an Octet HTX instrument (Sartorius) at 1000 rpm and 25 °C. All proteins were diluted in an assay buffer (PBS, 1 % BSA, 0.05% Tween 20). Test and control antibodies at a concentration of 2 pg/ml were first captured on AHQ biosensors to achieve the binding signals of 0.8-1 .3 nm. Unoccupied Fc-binding sites on the antibody-coated sensors were subsequently quenched by 20 pg/mL of the Fc protein. After equilibration with the assay buffer, the biosensors were then dipped for 600 s into wells containing 5-fold serial dilution of Integrin-beta 2 complexes (association phase), followed by a transfer back into an assay buffer for additional 600 s (dissociation phase). Assay buffer alone served as a negative control. Binding response data were reference subtracted and were globally fitted with 1 :1 binding model using ForteBio's Octet Systems software 9.0.

ELISA

The ELISA protocol to assess interactions of the antibodies with unrelated macromolecules was adapted from Meirsch et al. (J Vis Exp. 2015 Jan 17;(95):51492). The tested antigens included Integrin AL/B2 (50 pg/mL, R&D systems 3868-AV-050), integrin AX/B2 (50 pg/mL, R&D systems 5755-AX-050), integrin AM/B2 (50 pg/mL, R&D systems 4047-AM-050), histidine tagged Sumo domain (100 pg/mL, recombinant), biotinylated Robo domain (100 pg/mL, recombinant), neutravidin (100 pg/mL, Pierce TPPI31000) or all other integrins proteins (50 pg/mL R&D systems). In addition, the binding of each antibody was also tested against empty wells (BSA only control) and wells containing goat anti-human Fc antibody (positive control, 1 pg/ml, Jackson 109-005-098). The antigens were coated at 30 pL per well in 384-well Maxisorp plates and incubated at 4°C overnight. Plates were blocked with 0.5% bovine serum albumin (BSA) for 1 hour at room temperature and washed with PBS + 0.05% Tween20. The Phage-Fab were added and allowed to bind for 60 min at room temperature. Plates were washed with PBS + 0.05% Tween20 and binding was detected with anti-M13 HRP antibody (1 :5000, Sinobiological 11973-MM05T-H ) and developed with the TMB substrate (KPL (Mandel) KP -50-76-03). Statistical analysis

[0063] All the statistical analysis were done using GraphPad Prism unless stated otherwise. The data have been represented as ± mean and p Value < 0.05 were considered statistically significant.

Anti-integrin beta-2 Antibodies

[0064] Provided herein are anti-integrin beta-2 antibodies that can be used for diagnostic and therapeutic purposes.

[0065] In some embodiments, an anti-integrin beta-2 antibody of the present disclosure has a KD less than about 10 nM.

[0066] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO:2 and an LCDR3 of SEQ ID NO:3. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3.

[0067] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:2. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:2. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:2 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:2.

[0068] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:3. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 3 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:3. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:3 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:3.

[0069] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO:2 or SEQ ID NO:3. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO:2 and having at least 95% identity to SEQ ID NO:2; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:3 and having at least 95% identity to SEQ ID NO:3.

[0070] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:4 or SEQ ID NO:5. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO:4 and an LCDR3 of SEQ ID NO:5. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID N0:4 and LCDR1 , LCDR2, and LCDR3 of SEQ ID N0:5.

[0071] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:4 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:4. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:4 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:4. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:4 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:4.

[0072] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:5 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:5. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 5 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:5. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:5 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:5.

[0073] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO:4 or SEQ ID NO:5. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO:4 or SEQ ID NO:5. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO:4 and having at least 95% identity to SEQ ID NO:4; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:5 and having at least 95% identity to SEQ ID NO:5.

[0074] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:6 or SEQ ID NO:7. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO:6 and an LCDR3 of SEQ ID NO:7. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:6 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:7.

[0075] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:6 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:6. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:6 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:6. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:6 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:6.

[0076] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:7 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:7. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:7 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:7. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:7 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:7.

[0077] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID N0:6 or SEQ ID NO:7. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO:6 or SEQ ID NO:7. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO:6 and having at least 95% identity to SEQ ID NO:6; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:7 and having at least 95% identity to SEQ ID NO:7.

[0078] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO:8 and an LCDR3 of SEQ ID NO:9. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:8 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:9.

[0079] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:8 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:8. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:8 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:8. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:8 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:8.

[0080] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:9 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:9. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:9 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:9. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:9 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:9.

[0081] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO:8 and having at least 95% identity to SEQ ID NO:8; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:9 and having at least 95% identity to SEQ ID NO:9.

[0082] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO: 10 or SEQ ID NO:11 . In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO: 10 and an LCDR3 of SEQ ID NO:11. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NQ:10 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:11.

[0083] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 10 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO: 10. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 10 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO: 10. In some embodiments, an anti- integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 10 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NQ:10. [0084] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 11 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO:11. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:11 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:11. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 11 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO: 11 .

[0085] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO: 10 or SEQ ID NO:11. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO: 10 or SEQ ID NO:11. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO: 10 and having at least 95% identity to SEQ ID NO: 10; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:11 and having at least 95% identity to SEQ ID NO:11 .

[0086] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO:12 or SEQ ID NO:13. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO: 12 and an LCDR3 of SEQ ID NO: 13. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:12 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:13.

[0087] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 12 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO: 12. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 12 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO: 12. In some embodiments, an anti- integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 12 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:12.

[0088] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 13 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO: 13. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 13 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:13. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 13 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO: 13.

[0089] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO: 12 or SEQ ID NO: 13. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO: 12 or SEQ ID NO: 13. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO: 12 and having at least 95% identity to SEQ ID NO: 12; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:13 and having at least 95% identity to SEQ ID NO: 13.

[0090] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure has at least one, at least two, or three CDRs of a variable domain sequence of SEQ ID NO: 14 or SEQ ID NO: 15. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises an HCDR3 of SEQ ID NO: 14 and an LCDR3 of SEQ ID NO: 15. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO:14 and LCDR1 , LCDR2, and LCDR3 of SEQ ID NO:15.

[0091] In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 14 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO: 14. In some embodiments, an anti-integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 14 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO: 14. In some embodiments, an anti- integrin beta-2 binding domain comprises an HCDR1 , HCDR2, and HCDR3 of SEQ ID NO: 14 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO:14.

[0092] In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 15 in which one of the CDRs comprises a substitution relative to the corresponding CDR set forth in SEQ ID NO: 15. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 15 in which two of the CDRs comprise a substitution relative to the corresponding CDRs set forth in SEQ ID NO:15. In some embodiments, an anti-integrin beta-2 binding domain comprises an LCDR1 , LCDR2, and LCDR3 of SEQ ID NO: 15 in which all three of the CDRs comprise a substitution relative to the corresponding CDR sequences set forth in SEQ ID NO: 15.

[0093] In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a variable region having at least 70%, 75%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of a variable region sequence of SEQ ID NO: 14 or SEQ ID NO: 15. In some embodiments, the variable domain comprises substitutions, insertions, or deletions in the framework of a variable region as shown in SEQ ID NO: 14 or SEQ ID NO: 15. In some embodiments, an anti-integrin beta-2 binding domain of the present disclosure comprises a heavy chain variable region comprising the HCD1 , HCDR2, and HCDR3 sequence of SEQ ID NO: 14 and having at least 95% identity to SEQ ID NO: 14; and a light chain variable region comprising the LCD1 , LCDR2, LCDR3 sequences of SEQ ID NO:15 and having at least 95% identity to SEQ ID NO: 15.

Antibody formats

[0094] An anti-integrin beta-2 antibody of the present disclosure may be incorporated into a bivalent antibody or a multivalent antibody that binds to the same, or a different, antigen. In some embodiments, an anti-lntegrin beta-2 antibody of the present disclosure may be incorporated into a bispecific antibody or multispecific antibody that binds to the antigen at different epitopes, or that binds to different antigens. In some embodiments, such an antibody may comprise an Fc region. In some embodiments, an anti-integrin beta-2 antibody of the present disclosure may be present as an antigen binding domain of a larger molecule, e.g., present as an antigen binding domain of a chimeric antigen receptor or synthetic Notch receptor.

Nucleic Acids and Vectors Encoding CARS

[0095] Any method may be used to genetically modify an effector cell, such as a T-cell or NK cell to express a CAR comprising an anti-integrin beta-2 antibody of the present disclosure. Non-limiting examples of methods of genetically engineering immune cells include, but are not limited to, retrovirus- or lentivirus-mediated transduction. Other viral delivery systems include adenovirus, adeno-associated virus, herpes simplex viral vectors, pox viral vectors, alphavirus vectors, poliovirus vectors, and other positive and negative stranded RNA viruses, viroids, and virusoids, or portions thereof. Methods of transduction include direct co-culture of the cells with producer cells, e.g., by the method of Bregni, et al. (Blood 80: 1418-1422 (1992), or culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and polycations, e.g., by the method of Xu, et al. Exp. Hemat. 22:223-230 (1994); and Hughes, et al. J. Clin. Invest. 89: 1817 (1992).

[0096] In some embodiments, genetic modification is performed using transposase-based systems for gene integration, CRISPR/Cas-mediated gene integration, TALENs or Zinc-finger nucleases integration techniques. For example, CRISPR/Cas-mediated gene integration may be employed to introduce a CAR or synthetic Notch receptor into immune effectors cells, which may then be selected and expanded for administration to a patient.

Antibody Conjugates

[0097] In a further aspect, an anti-integrin beta-2 antibody of the present disclosure may be conjugated or linked, either directly or indirectly, to therapeutic and/or imaging/detectable moieties. For example, in some embodiments, an antibody of the present disclosure, or an antigen binding region comprising an antibody of the present invention, may be conjugated to agents including, but not limited to, a detectable marker, a cytotoxic agent, an imaging agent, a therapeutic agent, or an oligonucleotide. Methods for conjugating or linking an antibody, or antigen binding regions comprising an antibody, to a desired molecule moiety are well known in the art. The moiety may be linked to the antibody covalently or by non-covalent linkages.

[0098] In some embodiments, an anti-integrin beta-2 antibody of the present disclosure, or an antigen binding domain comprising an anti-integrin beta-2 antibody of the present disclosure, is conjugated to cytotoxic moiety or other moiety that inhibits cell proliferation.

[0099] In some embodiments, an anti-integrin beta-2 antibody of the present disclosure is conjugated to a cytotoxic agent including, but not limited to, e.g., ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, methotrexact, actinomycin, a diphtheria toxin, extotoxin A from Pseudomonas, Pseudomonas exotoxin40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, restrictocin, cobran venom factor, a ribonuclease, engineered Shiga toxin, phenomycin, enomycin, curicin, crotin, calicheamicin, Saponaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolastatin, cc1065, or a cisplatin. In some embodiments, the antibody may be linked to an agent such as an enzyme inhibitor, a proliferation inhibitor, a lytic agent, a DNA or RNA synthesis inhibitors, a membrane permeability modifier, a DNA metabolite, a dichloroethylsulfide derivative, a protein production inhibitor, a ribosome inhibitor, or an inducer of apoptosis. [0100] In some embodiments, an anti-integrin beta-2 antibody of the present disclosure, or an antigen binding domain comprising an anti-lntegrin beta-2 antibody of the present disclosure, may be linked to a radionuclide, an iron-related compound, a dye, a fluorescent agent, or an imaging agent. In some embodiments, an antibody may be linked to agents, such as, but not limited to, metals; metal chelators; lanthanides; lanthanide chelators; radiometals; radiometal chelators; positron-emitting nuclei; microbubbles (for ultrasound); liposomes; molecules microencapsulated in liposomes or nanosphere; monocrystalline iron oxide nanocompounds; magnetic resonance imaging contrast agents; light absorbing, reflecting and/or scattering agents; colloidal particles; fluorophores, such as near-infrared fluorophores.

[0101] While the above description provides examples of one or more antibodies and nucleic acids it will be appreciated that other compositions of matter may be within the scope of the claims as interpreted by one of skill in the art.

Polypeptide Sequences:

SEQ ID NO: 1 Uniprot P05107-1 amino acid sequence

MLGLRPPLLA LVGLLSLGCV LSQECTKFKV SSCRECIESG PGCTWCQKLN

FTGPGDPDSI RCDTRPQLLM RGCAADDIMD PTSLAETQED HNGGQKQLSP

QKVTLYLRPG QAAAFNVTFR RAKGYPIDLY YLMDLSYSML DDLRNVKKLG

GDLLRALNEI TESGRIGFGS FVDKTVLPFV NTHPDKLRNP CPNKEKECQP

PFAFRHVLKL TNNSNQFQTE VGKQLISGNL DAPEGGLDAM MQVAACPEEI

GWRNVTRLLV FATDDGFHFA GDGKLGAILT PNDGRCHLED NLYKRSNEFD

YPSVGQLAHK LAENNIQPIF AVTSRMVKTY EKLTEIIPKS AVGELSEDSS

NWQLIKNAY NKLSSRVFLD HNALPDTLKV TYDSFCSNGV THRNQPRGDC

DGVQINVPIT FQVKVTATEC IQEQSFVIRA LGFTDIVTVQ VLPQCECRCR

DQSRDRSLCH GKGFLECGIC RCDTGYIGKN CECQTQGRSS QELEGSCRKD

NNSIICSGLG DCVCGQCLCH TSDVPGKLIY GQYCECDTIN CERYNGQVCG

GPGRGLCFCG KCRCHPGFEG SACQCERTTE GCLNPRRVEC SGRGRCRCNV

CECHSGYQLP LCQECPGCPS PCGKYISCAE CLKFEKGPFG KNCSAACPGL

QLSNNPVKGR TCKERDSEGC WVAYTLEQQD GMDRYLIYVD ESRECVAGPN

IAAIVGGTVA GIVLIGILLL VIWKALIHLS DLREYRRFEK EKLKSQWNND NPLFKSATTT VMNPKFAES

SEQ ID NO: 2 Antibody-7065 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTISYYYMHWVRQAPGKGLEWVASISSSSGY

TYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGAMDYWGQGTLVTVSS

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ

SSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKP

REEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HCDR1 : ISYYYM

HCDR2: SISSSSGYTY

HCDR3: GAM

SEQ ID NO: 3 Antibody-7065 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQFSSGSWAPITFGQGTKVEIKRTVAAPS

VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS

TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: FSSGSWAPI

SEQ ID NO: 4 Antibody-7060 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTLSYSSMHWVRQAPGKGLEWVAYIYPSYG

YTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWSPGSGWAFDYWGQ

GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL

DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

HCDR1 : LSYSSM

HCDR2: YIYPSYGYTY

HCDR3: WSPGSGWAF

SEQ ID NO: 5 Antibody-7060 light chain variable region; CDRs are underlined DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYHGSLITFGQGTKVEIKRTVAAPSVFIF

PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL

SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: YHGSLI

SEQ ID NO: 6 Antibody-7062 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTISSYSIHWVRQAPGKGLEWVASIYSYYGYT

SYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWGYPYAMDYWGQGTL

VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF

PAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP

CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN

AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD

GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

HCDR1 : ISSYSI

HCDR2: SIYSYYGYTS

HCDR3: YWGYPYAM

SEQ ID NO: 7 Antibody-7062 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYYYAASLFTFGQGTKVEIKRTVAAPSV

FIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST

YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: YYYAASLF

SEQ ID NO: 8 Antibody-7063 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTLSYSYMHWVRQAPGKGLEWVASIYSYYS

STSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYHYSYYAGLDYWGQ

GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL

DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

HCDR1 : LSYSYM

HCDR2: SIYSYYSSTS

HCDR3: SYHYSYYAGL

SEQ ID NO: 9 Antibody-7063 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWYFLITFGQGTKVEIKRTVAAPSVFIFP

PSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS

STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: WYFLI SEQ ID NO: 10 Antibody-7064 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTLSYSSMHWVRQAPGKGLEWVAYIYSSSG

YTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGWYAHAGMDYWGQ

GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV

HTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL

DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

HCDR1 : LSYSSM

HCDR2: YIYSSSGYTY

HCDR3: WGWYAHAGM

SEQ ID NO: 11 Antibody-7064 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWVHGL1TFGQGTKVEIKRTVAAPSVFI

FPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS

LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: WVHGLI

SEQ ID NO: 12 Antibody-7056 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTLYYYSMHWVRQAPGKGLEWVAYIYPYYG

YTSYADSVKGRFTISADTS KNTAYLQM N S LRAE DTAVYYCARTVRGSKKPYFSGWAM

DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT

ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

HCDR1 : LYYYSM

HCDR2: YIYPYYGYTS

HCDR3: TVRGSKKPYFSGWAM

SEQ ID NO: 13 Antibody-7056 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWGAWGPLJTFGQGTKVEIKRTVAAPS

VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS

TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: WGAWGPLI

SEQ ID NO: 14 Antibody-7341 heavy chain variable region; CDRs are underlined

EVQLVESGGGLVQPGGSLRLSCAASGFTLSYYYMHWVRQAPGKGLEWVASISSYYG

YTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGALDYWGQGTLVTVS

SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL

QSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP

ELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTK

PREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL

YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HCDR1 : LSYYYM

HCDR2: SISSYYGYTS

HCDR3: GAL

SEQ ID NO: 15 Antibody-7341 light chain variable region; CDRs are underlined

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGV

PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQFYGGYSLJTFGQGTKVEIKRTVAAPSV

FIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST

YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

LCDR1 : SVSSA

LCDR2: SASSLYS

LCDR3: FYGGYSLI

Claims

Claims:

1. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising ISYYYM, an HCDR2 sequence comprising SISSSSGYTY; and an HCDR3 sequence comprising GAM; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising FSSGSWAPI.

2. The antibody of claim 1 , wherein the VH comprises an amino acid sequence having at least 95% identity to SEQ ID NO:2; and/or wherein the VL comprises an amino acid sequence having at least 95% identity to SEQ ID NO:3.

3. The antibody of claim 1 , wherein the VH comprises amino acid sequence SEQ ID NO:2; and/or wherein the VL comprises amino acid sequence SEQ. ID NO:3.

4. The antibody of any one of claims 1-3, wherein the antibody is a single chain variable fragment (scFv).

5. The antibody of claim 4, wherein the VL is N-terminal to the VH.

6. The antibody of claim 4, wherein the VH is N-terminal to the VL.

7. The antibody of any one of claims 5-6, wherein the VH and the VL are separated by a flexible linker. The antibody of claim 7, wherein the flexible linker comprises Gly-Ser. The antibody of claim 8, wherein the flexible linker comprises one or more Gly-Ser sequences. A bispecific or multispecific antibody comprising the antibody of any one or claims 1-9. A chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody of any one of claims 1-9. An immune effector cell comprising the CAR of claim 11 . The immune effector cell of claim 12, wherein the cell is a T-cell or an NK cell. A polynucleotide encoding an antibody of any one of claims 1-11. A vector comprising the polynucleotide of claim 14. An immune effector cell comprising the vector of claim 15. A nucleic acid encoding an antibody VH and/or VL, wherein the VH comprises an HCDR1 sequence comprising ISYYYM, an HCDR2 sequence comprising SISSSSGYTY; and an HCDR3 sequence comprising GAM; and wherein the VL comprises an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising FSSGSWAPI. The nucleic acid of claim 17, wherein the VH comprises an amino acid sequence having at least 95% identity to SEQ. ID NO:2 and/or wherein the VL comprises an amino acid sequence having at least 95% identity to SEQ. ID NO:3. The nucleic acid of claim 17, wherein the VH comprises amino acid sequence SEQ ID NO:2; and/or wherein the VL comprises amino acid sequence SEQ ID NO: 3. A vector comprising the nucleic acid of any one of claims 17-19. A host cell comprising the vector of claim 20. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising LSYSSM, an HCDR2 sequence comprising YIYPSYGYTY; and an HCDR3 sequence comprising WSPGSGWAF; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising YHGSLI. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising LYYYSM, an HCDR2 sequence comprising YIYPYYGYTS; and an HCDR3 sequence comprising TVRGSKKPYFSGWAM; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising WGAWGPLI. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising LSYYYM, an HCDR2 sequence comprising SISSYYGYTS; and an HCDR3 sequence comprising GAL; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising FYGGYSLI. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising ISSYSI, an HCDR2 sequence comprising SIYSYYGYTS; and an HCDR3 sequence comprising YWGYPYAM; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising YYYAASLF. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising LSYSYM, an HCDR2 sequence comprising SIYSYYSSTS; and an HCDR3 sequence comprising SYHYSYYAGL; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising WYFLI. An antibody that specifically binds to integrin beta-2, wherein the antibody comprises an integrin beta-2 binding domain comprising: a heavy chain variable region (VH) comprising an HCDR1 sequence comprising LSYSSM, an HCDR2 sequence comprising YIYSSSGYTY; and an HCDR3 sequence comprising WGWYAHAGM; and a light chain variable region (VL) comprising an LCDR1 sequence comprising SVSSA, an LCDR2 sequence comprising SASSLYS; and an LCDR3 sequence comprising WVHGLI.